hsa-miR-26b

ncRNA information

ncRNA name

hsa-miR-26b

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

ATF2

Cancer information

Cancer name

Laryngeal Cancer

Cancer site

Larynx

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R.

Tissue resource

human laryngeal cancer cell lines Hep-2

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Shanghai Institute for Biological Sciences, Chinese Academy of Sciences

Country

China

Continent

Asia